We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Green Light Therapy Could Cut Migraine Intensity and Frequency
News

Green Light Therapy Could Cut Migraine Intensity and Frequency

Green Light Therapy Could Cut Migraine Intensity and Frequency
News

Green Light Therapy Could Cut Migraine Intensity and Frequency

Credit: Kelly Lacy/ Pexels
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Green Light Therapy Could Cut Migraine Intensity and Frequency"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

New research from the University of Arizona Health Sciences found that people who suffer from migraine may benefit from green light therapy, which was shown to reduce the frequency and intensity of headaches and improve patient quality of life.


According to the Migraine Research Foundation, migraine is the third most prevalent illness in the world, affecting 39 million people in the United States and 1 billion worldwide.


"This is the first clinical study to evaluate green light exposure as a potential preventive therapy for patients with migraine," said lead study author Dr. Mohab Ibrahim, an associate professor in the UArizona College of Medicine – Tucson's anesthesiologypharmacology and neurosurgery departments and director of the Chronic Pain Management Clinic. "As a physician, this is really exciting. Now, I have another tool in my toolbox to treat one of the most difficult neurological conditions – migraine."


Overall, green light exposure reduced the number of headache days per month by an average of about 60%. A majority of study participants – 86% of episodic migraine patients and 63% of chronic migraine patients – reported a more than 50% reduction in headache days per month. Episodic migraine is characterized by up to 14 headache days per month, while chronic migraine is 15 or more headache days per month.


"The overall average benefit was statistically significant. Most of the people were extremely happy," Ibrahim said of the participants, who were given light strips and instructions to follow while completing the study at home. "One of the ways we measured participant satisfaction was, when we enrolled people, we told them they would have to return the light at the end of the study. But when it came to the end of the study, we offered them the option to keep the light, and 28 out of the 29 decided to keep the light."


Ibrahim and co-author Dr. Amol Patwardhan, who are affiliated with the UArizona Health Sciences Comprehensive Pain and Addiction Center, have been studying the effects of green light exposure for several years. This initial clinical study included 29 people, all of whom experience episodic or chronic migraine and failed multiple traditional therapies, such as oral medications and Botox injections.


"Despite recent advances, the treatment of migraine headaches is still a challenge," said Patwardhan, an associate professor and the vice chair of research in the Department of Anesthesiology. "The use of a nonpharmacological therapy such as green light can be of tremendous help to a variety of patients that either do not want to be on medications or do not respond to them. The beauty of this approach is the lack of associated side effects. If at all, it appears to improve sleep and other quality of life measures."


During the study, patients were exposed to white light for one to two hours a day for 10 weeks. After a two-week break, they were exposed to green light for 10 weeks. They completed regular surveys and questionnaires to track the number of headaches they experienced and the intensity of those headaches, as well as quality of life measurements such as the ability to fall and stay asleep or to perform work.


Using a numeric pain scale of zero to 10, participants noted that green light exposure resulted in a 60% reduction in pain, from 8 to 3.2. Green light therapy also shortened the duration of headaches, and it improved participants' ability to fall and stay asleep, perform chores, exercise, and work.


None of the study participants reported any side effects of green light exposure.


"In this trial, we treated green light as a drug," Ibrahim said. "It's not any green light. It has to be the right intensity, the right frequency, the right exposure time and the right exposure methods. Just like with medications, there is a sweet spot with light."


Ibrahim has been contacted by physicians from as far away as Europe, Africa and Asia, all asking for the green light parameters and schematic design for their own patients.


"As you can imagine, LED light is cheap," he said. "Especially in places where resources are not that available and people have to think twice before they spend their money, when you offer something affordable, it's a good option to try."


The paper, "Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial," was published online by Cephalalgia, the journal of the International Headache Society.


"These are great findings, but this is where the story begins," Ibrahim said. "As a scientist, I am really interested in how this works because if I understand the mechanism, then I can utilize it for other conditions. I can use it as a tool to manipulate the biological systems to achieve as much as we can."


Reference: Martin LF, Patwardhan AM, Jain SV, et al. Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial. Cephalalgia. 2021;41(2):135-147. doi: 10.1177/0333102420956711


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement